New Research May Link HIV Drugs to Alzheimer’s Prevention

Recent studies suggest that certain existing HIV medications could potentially serve as a preventive treatment for Alzheimer’s disease. These drugs, known as nucleoside reverse transcriptase inhibitors (NRTIs), are usually employed to manage HIV, but researchers from the University of Virginia have discovered a correlation between their use and a reduced risk of developing Alzheimer’s.

Dr. Jayakrishna Ambati, who leads the study and is a professor at UVA, noted that individuals using NRTIs might see a significant annual decline in Alzheimer’s risk. There’s a compelling connection here—researchers analyzed 24 years of health insurance data involving around 270,000 patients to arrive at their conclusions.

Findings published in the Journal of Alzheimer’s Disease and Dementia highlight that the risk reduction among those taking NRTIs was notably higher than expected. Currently, the UVA team is looking to initiate clinical trials for these drugs in relation to Alzheimer’s treatment.

Every year, nearly 10 million people are newly diagnosed with common dementia globally. According to Dr. Ambati, if these drugs indeed offer protective benefits, it could mean 60,000 fewer Alzheimer’s cases annually in the U.S., with potentially up to a million cases prevented worldwide.

NRTIs not only hinder the replication of HIV but also seem to stop the activation of inflammasomes, which are proteins implicated in Alzheimer’s development. Dr. Ambati expressed astonishment at the extent of protection these drugs appeared to provide.

“There’s a very good chance that this drug will help prevent Alzheimer’s.”

While Dr. Marc Siegel, a senior medical analyst, commented on the implications of these findings, he emphasized that the study was observational in nature. He described inflammasomes as intracellular proteins that trigger inflammatory responses, suggesting that the connection to HIV might reveal more about the immune system’s intricacies.

Dr. Rebecca Edelmeyer of the Alzheimer’s Disease Association also found the study’s results intriguing. She pointed out that repurposing existing drugs like NRTIs could present a “promising route” for future treatments, especially since their safety profiles are already established. However, she cautioned that further research and rigorously designed clinical trials are essential to validate these findings comprehensively.

Looking Ahead

The research team did note certain limitations. Dr. Ambati mentioned that while their study indicated a link between NRTIs and Alzheimer’s risk, it doesn’t establish a direct cause-and-effect relationship. However, the consistent findings across various databases enhance the reliability of their results.

Dr. Siegel added that the unique action of NRTIs differentiates them from other HIV medications and suggests a specific impact on Alzheimer’s risk. Researchers are also optimistic about a new drug called K9, which like NRTIs, blocks inflammasomes but is expected to be safer and more effective.

As exciting as these developments are, Ambati warned that individuals shouldn’t start taking NRTIs purely for Alzheimer’s prevention unless they are part of clinical trials. Interested parties should monitor such opportunities closely, especially for patients who might be affected.

In the U.S., approximately 7 million people live with Alzheimer’s today, a number projected to reach 13 million by 2050.

This study received partial funding from the UVA Strategic Investment Fund and the National Institutes of Health.